Media stories about Grifols SA, Barcelona (NASDAQ:GRFS) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.7515086494397 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research firms have recently weighed in on GRFS. ValuEngine upgraded Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. BidaskClub upgraded Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Zacks Investment Research upgraded Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. UBS Group downgraded Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Finally, HSBC upgraded Grifols SA, Barcelona from a “reduce” rating to a “hold” rating in a research note on Wednesday. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Grifols SA, Barcelona presently has a consensus rating of “Hold” and an average price target of $23.00.
Shares of Grifols SA, Barcelona (NASDAQ:GRFS) traded down $0.07 during midday trading on Wednesday, reaching $21.46. The company’s stock had a trading volume of 198,966 shares, compared to its average volume of 609,361. Grifols SA, Barcelona has a fifty-two week low of $17.24 and a fifty-two week high of $25.18. The company has a current ratio of 3.01, a quick ratio of 1.35 and a debt-to-equity ratio of 1.62. The company has a market cap of $5,630.00, a P/E ratio of 23.08, a P/E/G ratio of 1.38 and a beta of 1.16.
WARNING: This report was published by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/2018/03/15/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-grifols-sa-barcelona-grfs-share-price/2032634.html.
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.